Alcon Inc. (ALC)
NEUTRALファンダメンタル
37
株価
$73.27
時価総額
$35.41B
パート1 · 企業の価値
概要
Alcon makes products for eye care: surgical equipment and disposable supplies used in cataract and vitreoretinal operations, plus contact lenses and eye drops sold over the counter and through optometrists. Spun off from Novartis in 2019 and domiciled in Switzerland, it is one of the largest companies focused solely on the eye, selling to surgeons, hospitals and eye-care practitioners worldwide.
収益の仕組み
The Surgical segment follows a razor-and-blade pattern: Alcon sells or places a surgical console or laser once, then earns recurring revenue for years from the consumables, lenses and service that surgeons must keep buying to use it. Vision Care behaves more like a consumer-health business, with contact lenses and eye drops repurchased regularly through optometrists and retail.
セグメント別売上高
Cataract and vitreoretinal surgical equipment, intraocular lenses (implantables) and the consumables surgeons use with them.
Contact lenses and ocular-health products such as lubricating eye drops, sold through optometrists and retail rather than surgeons.
競争優位性（moat）
スイッチングコスト · 狭いOnce a surgical practice is set up around Alcon's consoles, lens formulas and diagnostic tools, moving to a rival platform means retraining staff and requalifying equipment, which keeps buyers locked into Alcon's consumables. The advantage is real but not exclusive: Johnson & Johnson Vision, Bausch + Lomb and Zeiss compete for the same installed-base strategy.
需要を左右する要因
ディフェンシブMost Surgical revenue tracks cataract surgery volumes, which are driven by an aging population and are rarely postponable once vision is impaired, so demand holds up better than in most medtech categories during downturns. Vision Care is a bit more discretionary but still tied to a recurring need rather than a one-off purchase.
主なリスク
- Reliance on single-source suppliers — The company relies on global supply chains and, for some components, on single-source suppliers; a disruption at one of them can halt production of a device or lens line with no quick substitute.
- Exposure to China and volatile markets — Alcon flags an increasingly challenging economic, political and legal environment in China as a risk factor, alongside broader exposure to currency and political volatility in the emerging markets where it sells.
- Cybersecurity and data privacy — The company cites cybersecurity and cloud-migration vulnerabilities, and the complexity of complying with data-privacy rules across the many jurisdictions where it operates, as ongoing risks to its business.
- Competition from large medtech rivals — Alcon competes against large, well-resourced eye-care and medical-device companies that can match its research spending and pursue the same installed-base strategy, pressuring both pricing and market share.
強気材料
Buyers argue that Alcon's installed base of roughly 28,000 surgical systems locks in years of recurring consumables revenue, that cataract surgery demand is structurally supported by an aging population, and that new product launches keep growth ahead of the broader eye-care market.
弱気材料
Sellers fear that reliance on single-source suppliers and a difficult China environment could disrupt supply or demand with little warning, and that well-funded rivals pursuing the same installed-base strategy will eventually compress the pricing power that the consumables model depends on.
Written by the editors, published on 2026年8月18日
Direct competitors
Who this company fights with for the same customers
Generated on 2026年8月23日 with claude-opus-5 — shared with all users
CooperVision is a pure contact-lens rival named by both companies in their annual reports, disputing the same spherical, toric and multifocal lens prescriptions through the same optician and optometrist channel.
Alcon names Bausch & Lomb as a primary competitor in both of its segments, so the two go head to head across cataract surgery equipment and intraocular lenses as well as contact lenses and eye drops sold to the same eye-care professionals.
Its Johnson & Johnson Vision arm is the other global player Alcon names in both surgical and vision care, competing directly on premium intraocular lenses and, with the Acuvue brand, on daily disposable contact lenses.
Listed first among Alcon's surgical competitors, Zeiss sells the ophthalmic surgical platforms, refractive lasers and diagnostic systems that compete for the same capital budgets of cataract and refractive surgery clinics.
Hoya's Vision Care and medical divisions compete with Alcon on intraocular lenses implanted in cataract surgery, with particular strength in Japan and the rest of Asia.
Glaukos is the specialist rival Alcon names in surgical glaucoma, selling the micro-stents implanted during cataract surgery that compete directly with Alcon's own glaucoma devices for the same surgeons.
貸借対照表と流動性
売上高
$224M
直近12か月（2013/3/31まで）
純利益
$-40M
直近12か月（2013/3/31まで）
フリーキャッシュフロー
-
自己資本合計
$278M
負債合計
$238M
流動比率
0.18
利払い倍率
-
負債/EBITDA
2.20
一株当たり利益（EPS）
売上高と純利益
フリーキャッシュフロー
収益内訳
財務推移表
利益率の推移
負債の推移
負債の重さ
成長率グリッド
成長率 — 売上高
適正価値の推定
適正価値
$43.57
現在株価
$73.27
安全マージン
-68.2%
適正価値レンジ
$28.32 - $58.82
推定方法
バリュエーション指標
P/E レシオ
44.50
ROE
-9.4%
P/B レシオ
132.11
P/FCF
-
粗利益率
-
ROIC
-13.2%
収益性レーダー
Value Creation (Economic Moat)
ROIC
-13.2%
WACC
8.8%
ROIC − WACC
-22.0 pp
ROIC is below the cost of capital — the company is destroying value for every dollar invested.
ファンダメンタル分析基準
合格（6）
- Debt/Equity ratio
- Debt/EBITDA
- Low reliance on intangibles
- Revenue Growth 5Y 8.8%
- Analyst Consensus 80% Buy
- Share Dilution -0.3%
不合格（11）
- Price CAGR 3.84%
- ROIC -13.2%
- P/B Ratio 132.11
- Operating Margin -24.4%
- Current Ratio
- Return on Tangible Assets
- DCF valuation (Unknown)
- ROE 3.7%
- Earnings Surprise avg 2.3%
- Net Margin Trend -17.8% vs 10.6%
- Piotroski F-Score 2/9
データなし（10）
- EPS data insufficient
- Gross Margin NaN%
- P/FCF NaN
- Dividend Payout NaN%
- Positive Free Cash Flow
- CapEx intensity
- Interest Coverage
- Price below Graham Number
- PEG Ratio (need PE > 0 and growth > 0)
- Earnings Quality (OCF/Net Income)
Piotroski F-スコア
重大な財務上の懸念
利益の質
低品質：会計処理を調査してください
株式希薄化
株式を買い戻している。株主に友好的
ガバナンス
経営陣
| 氏名 | 役職 | 年齢 |
|---|---|---|
| Mr. David J. Endicott | CEO & Director | 60 |
| Mr. Timothy C. Stonesifer | Senior VP & CFO | 58 |
| Mr. Ian Bell | Senior VP & COO | 54 |
| Margaret Buckley | Chief Accounting Officer | - |
| Dr. Franck Leveiller Ph.D. | SVP of Global Research & Development and Chief Scientific Officer | - |
| Mr. Muru Murugappan | Senior VP and Chief Information & Transformation Officer | - |
| Mr. Daniel Cravens | Vice President of Investor Relations | - |
| Mr. Royce R. Bedward J.D. | Senior VP, General Counsel & Corporate Secretary | 59 |
| Ms. Kimberly Martin | Senior VP and Chief HR & Corporate Communications | 50 |
| Mr. Leon Sergio Duplan Fraustro | Senior VP & President of Americas | 57 |
監査リスク
9
取締役会リスク
4
報酬リスク
3
株主権利リスク
1
パート2 · 株価と買い時
この部分は企業に価値があるかを判断するものではありません。ファンダメンタルズに納得したうえで、いつ買うかを選ぶためのものです。内容：テクニカル分析、ポテンシャル、過去のドローダウン、ガンマエクスポージャー。
Latest News
Recent headlines for ALC, sourced from Markets Gazette.
- 2/25/2026NEUTRALAlcon (ALC) Q4 2025 Earnings Call Transcript
Markets Gazette announces the availability of the Alcon (ALC) Q4 2025 earnings call transcript. This routine event for publicly traded companies provides investors and analysts with a detailed account of discussions between management and the financial community. While the specific content of the results and projections has not yet been disclosed in this announcement, the publication of the transcript is a crucial step for transparency and in-depth analysis of the company's performance. Market participants are now awaiting to examine the details to assess Alcon's financial health, future prospects, and potential impact on its stock price. The earnings call typically covers revenues, profits, margins, guidance, and future strategies, all critical elements for investment decisions.
via Markets Gazette